Regeneron, Sanofi Cut Heart Drug's Price to Spur Greater Use
- Praluent reduces heart events 15%, matching Amgen’s Repatha
- Sales focus narrowed to high-risk patients who respond best
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. and Sanofi are taking the unprecedented step of cutting the price of their $14,000-a-year heart drug Praluent and narrowing its use to high-risk patients shown to benefit most in an effort to get insurers to ease restrictions on its use.
A highly anticipated study of the injected drug found it reduces complications including heart attacks and strokes by 15 percent, less than the 20 percent benefit analysts say would be needed to force insurers to loosen their stranglehold.